Encapsulating Peritoneal Sclerosis: What Have We Learned?

Seminars in Nephrology

Volumn 31, Issue 2, 2011, Pages 183-198

  Goodlad, Catriona ^a   Brown, Edwina A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Encapsulating peritoneal sclerosis; Peritoneal dialysis

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; CYCLOSPORIN; DIALYSIS FLUID; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GLUCOSE; PENTOXIFYLLINE; PREDNISOLONE; STEROID; TAMOXIFEN; TRANILAST;

ANGIOGENESIS; ARTICLE; CLINICAL FEATURE; EPITHELIAL MESENCHYMAL TRANSITION; FIBRIN DEPOSITION; FIBROSIS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM LAVAGE; PERITONITIS; PRIORITY JOURNAL; RADIODIAGNOSIS; RISK ASSESSMENT; SCREENING; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; UREMIA;

EPITHELIAL-MESENCHYMAL TRANSITION; GLUCOSE; HUMANS; INCIDENCE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; TOMOGRAPHY, X-RAY COMPUTED; ULTRAFILTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952789596     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.01.007     Document Type: Article

References (100)

1. Eltringham W., Espiner H., Windsor C., et al. Sclerosing peritonitis due to practolol: a report on 9 cases and their surgical management. Br J Surg 1977, 64:229-235.
2. Lo W., Chan K., Leung A., Pang S., Tse C. Sclerosing peritonitis complicating prolonged use of chlorhexidine in alcohol in the connection procedure for continuous ambulatory peritoneal dialysis. Perit Dial Int 1991, 11:166-172.
3. Mekeel K., Moss A., Reddy K., Douglas D., Mulligan D. Sclerosing peritonitis and mortality after liver transplantation. Liver Transpl 2009, 15:435-439.
4. Johnson D., Cho Y., Livingston B., et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010, 77:904-912.
5. Kawanishi H., Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2005, 25(Suppl 4):S14-S18.
6. Brown M., Simpson K., Kerssens J., Mactier R. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009, 4:1222-1229.
7. Korte M., Yo M., Betjes M., et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007, 22:2412-2414.
8. Balasubramaniam G., Brown E., Davenport A., et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009, 24:3209-3215.
9. Kawaguchi Y., Saito A., Kawanishi H., et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005, 25(Suppl 4):S83-S95.
10. Kawanishi H., Kawaguchi Y., Fukui H., et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004, 44:729-737.
11. Kawanishi H., Watanabe H., Moriishi M., Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005, 25(Suppl 4):S39-S47.
12. Lambie M.L., John B., Mushahar L., Huckvale C., Davies S.J. The peritoneal osmotic conductance is low well before the diagnosis of EPS is made. Kidney Int 2010, 78:611-618.
13. Sampimon D., Coester A., Struijk D., Krediet R. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2011, 26:291-298.
14. Gupta S., Woodrow G. Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. Clin Nephrol 2007, 68:125-129.
15. Hur J., Kim K., Park M., Yu J. Abdominal cocoon: preoperative diagnostic clues from radiologic imaging with pathologic correlation. AJR Am J Roentgenol 2004, 182:639-641.
16. Hüser N., Stangl M., Lutz J., Fend F., Kreymann B., Gaa J. Sclerosing encapsulating peritonitis: MRI diagnosis. Eur Radiol 2006, 16:238-239.
17. Tarzi R., Frank J., Ahmad S., Levy J., Brown E. Fluorodeoxyglucose positron emission tomography detects the inflammatory phase of sclerosing peritonitis. Perit Dial Int 2006, 26:224-230.
18. Stafford-Johnson D., Wilson T., Francis I., Swartz R. CT appearance of sclerosing peritonitis in patients on chronic ambulatory peritoneal dialysis. J Comput Assist Tomogr 1998, 22:295-299. 1998.
19. Tarzi R., Lim A., Moser S., et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 2008, 3:1702-1710.
20. Vlijm A., Stoker J., Bipat S., et al. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2009, 29:517-522.
21. Honda K., Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005, 25(Suppl 4):S19-S29.
22. Williams J., Craig K., Topley N., et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002, 13:470-479.
23. Shimaoka T., Hamada C., Kaneko K., et al. Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. Nephrol Dial Transplant 2010, 25:3379-3385.
24. Honda K., Nitta K., Horita S., et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003, 19:169-175.
25. Yáñez-Mó M., Lara-Pezzi E., Selgas R., et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003, 348:403-413.
26. Aroeira L., Aguilera A., Sánchez-Tomero J., et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007, 18:2004-2013.
27. Del Peso G., Jiménez-Heffernan J., Bajo M., et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl 2008, 108:S26-S33.
28. Mateijsen M., van der Wal A., Hendriks P., et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999, 19:517-525.
29. Aroeira L., Aguilera A., Selgas R., et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005, 46:938-948.
30. De Vriese A., Tilton R., Stephan C., Lameire N. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001, 12:1734-1741.
31. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010, 21:212-222.
32. Margetts P., Bonniaud P., Liu L., et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005, 16:425-436.
33. De Vriese A., Tilton R., Mortier S., Lameire N. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006, 21:2549-2555.
34. Summers A., Brenchley P. An international encapsulating peritoneal sclerosis registry and DNA bank: why we need one now. Perit Dial Int 2006, 26:559-563.
35. Margetts P., Gyorffy S., Kolb M., et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002, 13:721-728.
36. Combet S., Ferrier M., Van Landschoot M., et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001, 12:2146-2157.
37. Miyata T., Horie K., Ueda Y., et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000, 58:425-435.
38. Davies S., Brown E., Frandsen N., et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005, 67:1609-1615.
39. Wong T., Phillips A., Witowski J., Topley N. Glucose-mediated induction of TGF-beta 1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int 2003, 63:1404-1416.
40. van Westrhenen R., Zweers M., Kunne C., de Waart D., van der Wal A., Krediet R. A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution. Perit Dial Int 2008, 28:487-496.
41. Lamb E., Cattell W., Dawnay A. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995, 47:1768-1774.
42. Honda K., Nitta K., Horita S., et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999, 14:1541-1549.
43. Boulanger E., Grossin N., Wautier M., Taamma R., Wautier J. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007, 71:126-133.
44. Hirahara I., Ishibashi Y., Kaname S., Kusano E., Fujita T. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant 2009, 24:437-447.
45. Noh H., Kim J., Han K., et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006, 69:2022-2028.
46. Mandl-Weber S., Haslinger B., Schalkwijk C., Sitter T. Early glycated albumin, but not advanced glycated albumin, methylglyoxal, or 3-deoxyglucosone increases the expression of PAI-1 in human peritoneal mesothelial cells. Perit Dial Int 2001, 21:487-494.
47. Davies S., Brown E. EAPOS: what have we learned?. Perit Dial Int 2007, 27:131-135.
48. Kang D., Hong Y., Lim H., Choi J., Han D., Yoon K. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int 1999, 19:221-230.
49. Fielding C., McLoughlin R., Parker C., et al. Recurrent peritonitis causes a dysregulation of the peritoneal cytokine network Presented at: Renal Association; 2008 May 16; Glasgow. http://www.renalarchive.org.
50. Hsu Y., Hsia C., Tsai D., Tu H., Hung K., Huang J. Development of encapsulating peritoneal sclerosis following bacterial peritonitis in a peritoneal dialysis patient. Am J Kidney Dis 2010, 55:198-202.
51. Margetts P., Kolb M., Galt T., Hoff C., Shockley T., Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001, 12:2029-2039.
52. Medcalf J., Walls J., Pawluczyk I., Harris K. Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells (HPMC): the role of TGF-beta. Nephrol Dial Transplant 2001, 16:1885-1892.
53. Hurst S., Wilkinson T., McLoughlin R., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
54. McLoughlin R., Jenkins B., Grail D., et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005, 102:9589-9594.
55. Oh K., Jung J., Yoon M., et al. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 2010, 25:1639-1646.
56. Sauter M., Cohen C., Wörnle M., Mussack T., Ladurner R., Sitter T. ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int 2007, 27:167-172.
57. Szeto C., Chow K., Poon P., Szeto C., Wong T., Li P. Genetic polymorphism of VEGF: impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 2004, 65:1947-1955.
58. Lee S., Kim B., Yang W., Kim S., Park S., Park J. High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney Int 2001, 60:55-64.
59. Dragomir E., Simionescu M. Monocyte chemoattractant protein-1-a major contributor to the inflammatory process associated with diabetes. Arch Physiol Biochem 2006, 112:239-244.
60. Malik A., Little M., Henriksson M., Tam F., Brown E. Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis. J Nephrol 2007, 20:340-349.
61. Ni J., Moulin P., Gianello P., Feron O., Balligand J., Devuyst O. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 2003, 14:3205-3216.
62. Ni J., McLoughlin R., Brodovitch A., et al. Nitric oxide synthase isoforms play distinct roles during acute peritonitis. Nephrol Dial Transplant 2010, 25:86-96.
63. Mizutani M., Ito Y., Mizuno M., et al. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Physiol Renal Physiol 2010, 298:F721-F733.
64. Ahmad S., North B., Qureshi A., et al. CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis. Eur J Clin Invest 2010, 40:1067-1073.
65. Nakamoto H., Imai H., Fukushima R., Ishida Y., Yamanouchi Y., Suzuki H. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008, 28(Suppl 3):S83-S87.
66. Rougier J., Guia S., Hagège J., Nguyen G., Ronco P. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1. Kidney Int 1998, 54:87-98.
67. Woodrow G., Augustine T., Brown E.A., et al. UK Encapsulating Peritoneal Sclerosis Clinical Practice Guidelines 2009 [accessed 2010 March 2]. http://www.renal.org/clinical/otherguidelines.
68. de Freitas D., Jordaan A., Williams R., et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int 2008, 28:271-276.
69. Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med 1991, 325:525-532.
70. Maruyama Y., Nakayama M. Encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2008, 28(Suppl 3):S201-S204.
71. Kuriyama S., Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2001, 16:1304-1305.
72. Yamamoto H., Nakayama M., Yamamoto R., et al. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Adv Perit Dial 2002, 18:135-138.
73. van Westrhenen R., Aten J., Hajji N., et al. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif 2007, 25:466-472.
74. Clark C., Vanderpool D., Preskitt J. The response of retroperitoneal fibrosis to tamoxifen. Surgery 1991, 109:502-506.
75. Selgas R, Aguilera A, Bajo A, et al. Effects of tamoxifen on epithelial-to-mesenchymal transition (EMT), fibrosis and angiogenesis of mesothelial cells. Paper presented: American Society of Nephrology, November 18, 2006; San Diego, CA.
76. Nilsson U., Abrahamsson A., Dabrosin C. Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits its nuclear translocation and anti-angiogenin therapy reduces breast cancer growth in vivo. Clin Cancer Res 2010, 16:3659-3669.
77. Korte M., Fieren M., Sampimon D., et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS study Nephrol Dial Transplant. [cited 2010 June 27]. http://www.ndt.oxfordjournals.org.
78. Eltoum M., Wright S., Atchley J., Mason J. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006, 26:203-206.
79. del Peso G., Bajo M., Gil F., et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003, 19:32-35.
80. Cushman M., Costantino J., Bovill E., et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol 2003, 120:109-116.
81. Kittur D., Korpe S., Raytch R., Smith G. Surgical aspects of sclerosing encapsulating peritonitis. Arch Surg 1990, 125:1626-1628.
82. Kawanishi H., Moriishi M., Ide K., Dohi K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int 2008, 28(Suppl 3):S205-S210.
83. Summers A., Pararajasingham R., Tavakoli A., et al. The role, timing and technique of surgery in the management of encapsulating peritoneal sclerosis Presented at: the Renal Association; 2009 April 21; Liverpool. http://www.renalarchive.org.
84. Brown E., Van Biesen W., Finkelstein F., et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009, 29:595-600.
85. Choi H., Kim D., Lee T., et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008, 28:174-182.
86. Pajek J., Kveder R., Bren A., et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int 2008, 28:44-52.
87. Ahmad S., Sehmi J., Ahmad-Zakhi K., Clemenger M., Levy J., Brown E. Impact of new dialysis solutions on peritonitis rates. Kidney Int Suppl 2006, 103:S63-S66.
88. Williams J., Topley N., Craig K., et al. The Euro-Balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004, 66:408-418.
89. Yang F., Chung A., Huang X., Lan H. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 2009, 54:877-884.
90. Noh H., Ha H., Yu M., Kim Y., Kim J., Lee H. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005, 25:38-47.
91. Duman S., Wieczorowska-Tobis K., Styszynski A., Kwiatkowska B., Breborowicz A., Oreopoulos D. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial 2004, 20:31-36.
92. Kolesnyk I., Noordzij M., Dekker F., Boeschoten E., Krediet R. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009, 24:272-277.
93. Ke C., Lee C., Lee C., Subeq Y., Lee R., Hsu B. Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats. Eur J Clin Invest 2010, 40:301-309.
94. Moriishi M., Kawanishi H., Kawai T., et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002, 18:149-153.
95. Yamamoto T., Nagasue K., Okuno S., Yamakawa T. The role of peritoneal lavage and the prognostic significance of mesothelial cell area in preventing encapsulating peritoneal sclerosis. Perit Dial Int 2010, 30:343-352.
96. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004, 15:1-12.
97. Kaneko K., Hamada C., Tomino Y. Peritoneal fibrosis intervention. Perit Dial Int 2007, 27(Suppl 2):S82-S86.
98. Goodlad C., Tarzi R., Gedroyc W., Lim A., Moser S., Brown E.A. Screening for encapsulating peritoneal sclerosis in peritoneal dialysis patients: role of CT scanning Nephrol Dial Transplant. [cited 2010 September 1]. http://www.ndt.oxfordjournals.org.
99. Hirahara I., Inoue M., Okuda K., Ando Y., Muto S., Kusano E. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan. Nephrol Dial Transplant 2007, 22:560-567.
100. Sampimon D., Korte M., Barreto D., et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2010, 30:163-169.